Mild to Moderate Psoriasis Clinical Trial
Official title:
Optimising Outpatient Care in Mild to Moderate Psoriasis by a Newly Developed 'Topical Treatment Optimising Programme' - an International Study Using Daivobet®/Dovobet® Gel
A Topical Treatment Optimisation Programme (TTOP) has been developed by the sponsor together with Patient Boards and an Expert Advisory Board to overcome non-adherence problems.
A Topical Treatment Optimisation Programme (TTOP) has been developed by the sponsor together with Patient Boards and an Expert Advisory Board. This tool is created to address patients' non-adherence in topical therapy and the resulting underperformance of such treatments in controlling psoriatic disease. The study addresses the effect of the relationship between the patient and the health care professional, one of the important factors that can affect treatment adherence and therapeutic efficacy. The TTOP will be compared to standardised regular care (called 'non-TTOP'). It is intended to clinically show the importance of an optimised contact between the patient and health care professional. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03222622 -
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
|
Phase 2 | |
| Completed |
NCT02529956 -
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
|
Phase 1 | |
| Withdrawn |
NCT00788424 -
Topical Application of AS101 for the Treatment of Psoriasis
|
Phase 2 | |
| Recruiting |
NCT05249972 -
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
|
Phase 3 | |
| Recruiting |
NCT05965089 -
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
|
Phase 1 | |
| Completed |
NCT01000714 -
Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis
|
Phase 2 |